BioPharmSignal logoBioPharmSignal

Biotech News

MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics (MLTX)MoonLake ImmunotherapeuticsEarnings

Biologics License Application for sonelokimab submitted to the U.S. Food and Drug Administration for the treatment of adults and adolescents with moderate-to-severe hidradenitis suppurativa, marking an important step towards potential U.S. approval and commercialization Positive Week 16 results

Related news

SNGXSOLIGENIX2026-11-06 12:30 EST

Soligenix Announces Recent Updates and Third Quarter 2026 Financial Results

AVTXAvalo Therapeutics2026-11-05 12:00 EST

Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates

SABSSAB Biotherapeutics2026-10-29 12:30 EST

SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET

KNSAKiniksa2026-10-27 11:30 EST

Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution

ZURAZura Bio2026-10-27 11:30 EST

Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates

BNTXBioNTech2026-10-20 10:45 EST

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

ARGXArgenx2026-10-15 05:00 EST

argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026

NRIXNurix Therapeutics2026-10-12 20:05 EST

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

REGNRegeneron Pharmaceuticals2026-09-24 20:05 EST

Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026

CABACabaletta Bio2026-11-05 12:30 EST

Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

View all latest news

MoonLake Immunotherapeutics

Nanobody-Based Immunology MoonLake Immunotherapeutics develops therapies for inflammatory diseases using Nanobodies, compact antibody-derived proteins designed for tissue penetration, molecular stability and multivalent target binding. Sonelokimab Sonelokimab is a trivalent Nanobody that binds IL-17A and IL-17F while also interacting...

Recent company news

MLTXMoonLake Immunotherapeutics2026-11-04 12:00 EST

MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update

MLTXMoonLake Immunotherapeutics2026-08-10 11:00 EST

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

MLTXMoonLake Immunotherapeutics2026-06-24 03:08 EST

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

MLTXMoonLake Immunotherapeutics2026-06-22 20:01 EST

MoonLake Immunotherapeutics Announces Proposed Public Offering

MLTXMoonLake Immunotherapeutics2026-06-21 21:00 EST

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

Stock data

Close
10.80 USD
Market cap
1.32B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States